Pfizer’s Covid-19 vaccine candidate prevented over 90% of infections
With effectiveness for the Covid-19 vaccines previously expected to be 60%-70%, ‘more than 90% is extraordinary,’ BioNTech CEO Ugur Sahin says
09 November 2020 - 16:15
New York/Berlin — The Covid-19 vaccine being developed by Pfizer and BioNTech prevented more than 90% of infections in a study of tens of thousands of volunteers, the most encouraging scientific advance so far in the battle against the coronavirus.
Eight months into the worst pandemic in a century, the preliminary results pave the way for the companies to seek an emergency-use authorisation from regulators if further research shows the shot is also safe...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.